SI-BONE To Report Third Quarter 2024 Financial Results on November 12, 2024

SIBN 10.22.2024

SERA-AI Powered Highlights
Date of Upcoming Event:2024-11-12
Name of Upcoming Event:Earnings Call
Full Press ReleaseSEC FilingsOur SIBN Tweets

About Gravity Analytica

Recent News

  • 01.13.2025 - SI-BONE Announces Preliminary Revenue for the Fourth Quarter and Full Year 2024
  • 12.04.2024 - Piper Sandler Healthcare Conference
  • 11.20.2024 - SI-BONE To Present at Piper Sandler 36th Annual Healthcare Conference on December 4, 2024

Recent Filings

  • 01.13.2025 - EX-99.1 EX-99.1
  • 01.13.2025 - 8-K Current report
  • 01.06.2025 - 4 Statement of changes in beneficial ownership of securities
PDF Version

SANTA CLARA, Calif.,Oct. 22, 2024(GLOBE NEWSWIRE) --SI-BONE, Inc.(Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced it will report financial results for the third quarter of 2024 after market close onTuesday, November 12, 2024. Management will host a corresponding conference call beginning at1:30 p.m. Pacific Time/4:30 p.m. Eastern Time.

Investors interested in listening to the conference call may do so by registering at this link:https://edge.media-server.com/mmc/p/b8oqnu9r. Live audio of the webcast will be available on the “Investors” section of the company’s website at:www.si-bone.com. The webcast will be archived and available for replay for at least 90 days after the event.

AboutSI-BONE, Inc.

SI-BONE(NASDAQ: SIBN) is a global leader in technology for the surgical treatment of sacropelvic disorders. Since pioneering minimally invasive surgery of the SI joint in 2009,SI-BONEhas supported over 3,900 surgeons in performing more than 100,000 sacropelvic procedures. A unique body of clinical evidence supports the use of SI-BONE’s technologies, including two randomized controlled trials and over 135 peer-reviewed publications.SI-BONEhas leveraged its leadership in minimally invasive SI joint fusion to commercialize novel solutions for adjacent markets, including adult deformity, spinopelvic fixation, and pelvic trauma.

For additional information on the company or the products including risks and benefits, please visitwww.si-bone.com.

iFuse Bedrock Granite, iFuse-TORQ, iFuse TORQ TNT,SI-BONE, and iFuse INTRA are registered trademarks ofSI-BONE, Inc.©2024SI-BONE, Inc.All Rights Reserved.

Investor Contact:Saqib Iqbalinvestors@si-bone.com

Primary Logo

Source: SI-BONE, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com